Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in: Drugs & Therapy Perspectives 1/2024

24-02-2024 | Borderline Personality Disorder | Disease Management

Treat borderline personality disorder with psychotherapy and concomitant psychiatric disorders with adjuvant pharmacotherapy

Authors: Esther S. Kim, Yvette N. Lamb

Published in: Drugs & Therapy Perspectives | Issue 1/2024

Login to get access

Abstract

No class of medications has consistently improved symptoms of borderline personality disorder (BPD) in randomized clinical trials, and no pharmacological treatment has been approved specifically for BPD. Psychotherapy is the treatment of first choice in BPD, and the general consensus is that pharmacotherapy should be used mainly for the treatment of comorbid disorders. However, most patients with BPD are medicated even when they do not have comorbidities.
Literature
1.
2.
3.
4.
Shah R, Zanarini MC. Comorbidity of borderline personality disorder: current status and future directions. Psychiatr Clin N Am. 2018;41(4):583–93.CrossRef
5.
Stone MH. Borderline personality disorder: clinical guidelines for treatment. Psychodyn Psychiatry. 2022;50(1):45–63.CrossRefPubMed
6.
7.
8.
Simonsen S, Bateman A, Bohus M, et al. European guidelines for personality disorders: past, present and future. Borderline Person Disord Emot Dysregul. 2019;6:9.CrossRef
9.
10.
Martín-Blanco A, Ancochea A, Soler J. Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder. Acta Psychiatr Scand. 2017;136(3):323–31.CrossRefPubMed
11.
Bozzatello P, Rocca P, De Rosa ML, et al. Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough? Expert Opin Pharmacother. 2020;21(1):47–61.CrossRefPubMed
12.
Soler J, Casellas-Pujol E, Fernández-Felipe I. “Skills for pills”: the dialectical-behavioural therapy skills training reduces polypharmacy in borderline personality disorder. Acta Psychiatr Scand. 2022;145(4):332–42.CrossRefPubMedPubMedCentral
Metadata
Title
Treat borderline personality disorder with psychotherapy and concomitant psychiatric disorders with adjuvant pharmacotherapy
Authors
Esther S. Kim
Yvette N. Lamb
Publication date
24-02-2024
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 1/2024
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-023-01042-9

Other articles of this Issue 1/2024

Drugs & Therapy Perspectives 1/2024 Go to the issue

Adis Drug Q&A

Efanesoctocog alfa in hemophilia A: a profile of its use

Correction

Correction to: Tezepelumab in severe asthma: a profile of its use

Systematic Review

Platelet-rich plasma therapy for chronic cutaneous wounds stratified by etiology: a systematic review of randomized clinical trials

Adis Drug Q&A

Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use

Practical Issues and Updates

Expand the treatment horizon of premenstrual dysphoric disorder with targeted therapeutic approaches

Practical Issues and Updates

Preferably pre-empt pathological scars, or pick from a plethora of therapies